Outcomes for patients with melanoma have improved over the past decade as a result of the
development and FDA approval of immunotherapies targeting cytotoxic T lymphocyte …

We concurrently examine the whole genome, transcriptome, methylome, and immune cell
infiltrates in baseline tumors from 77 patients with advanced cutaneous melanoma treated …

Background: Tumor mutational burden (TMB) is a genomic biomarker that can predict
favorable responses to immune checkpoint inhibitors (ICIs). Although we have better …

Background Immune checkpoint inhibitors (ICIs), targeting CTLA-4 or PD-1 molecules, have
shown impressive therapeutic results. However, only 20–40% of advanced melanoma …

Purpose: Adjuvant immunotherapy produces durable benefit for patients with resected
melanoma, but many develop recurrence and/or immune-related adverse events (irAE). We …

Background Metastasized or unresectable melanoma has been the first malignant tumor to
be successfully treated with checkpoint inhibitors. Nevertheless, about 40–50% of the …

Purpose Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte
associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic …

Abstract Background Immune checkpoint inhibitors (ICIs) have changed the clinical
management of melanoma. However, not all patients respond, and current biomarkers …

Melanoma is one of the most common cancers in Western countries but has defied the trend
of reductions in age-adjusted mortality observed in most other cancers in recent years …

In this study, we incorporate analyses of genome-wide sequence and structural alterations
with pre-and on-therapy transcriptomic and T cell repertoire features in immunotherapy …